Evidence map›Paper›PMID 24098553›Full record

ArticlePloS one2013

Circulating levels of human salusin-β, a potent hemodynamic and atherogenesis regulator.

Kazumi Fujimoto, Akinori Hayashi, Yuji Kamata, Akifumi Ogawa, Takuya Watanabe, Raishi Ichikawa, Yoshitaka Iso, Shinji Koba, Youichi Kobayashi, Takatoshi Koyama and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Serum salusin-α and -β levels in patients with parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Circulating prorenin: its molecular forms and plasma concentrations.Hypertension research : official journal of the Japanese Society of Hypertension · 2021
    Article
  7. Knockdown of Salusin-Oxidative medicine and cellular longevity · 2021
    Article
  8. Article
  9. Article
  10. Salusin-β Promotes Vascular CalcificationAntioxidants & redox signaling · 2019
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Salusin-Oxidative medicine and cellular longevity · 2017
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Kazumi FujimotoLaboratory of Molecular Genetics of Hematology, Graduate School of Health Care Sciences, Tokyo Medical and Dental University, Tokyo, Japan ; Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine, Kanagawa, Japan.
Akinori Hayashi
Yuji Kamata
Akifumi Ogawa
Takuya Watanabe
Raishi Ichikawa
Yoshitaka Iso
Shinji Koba
Youichi Kobayashi
Takatoshi Koyama
Masayoshi Shichiri
Kitasato University · JPShowa University · JPTokyo Medical and Dental University · JPTokyo University of Pharmacy and Life Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Using bioinformatics analysis, we previously identified salusin-β, an endogenous bioactive peptide with diverse physiological activities. Salusin-β is abundantly expressed in the neuroendocrine system and in systemic endocrine cells/macrophages. Salusin-β acutely regulates hemodynamics and chronically induces atherosclerosis, but its unique physicochemical characteristics to tightly adhere to all types of plastic and glassware have prevented elucidation of its precise pathophysiological role. To quantitate plasma total salusin-β concentrations, we produced rabbit and chicken polyclonal antibodies against the C- and N-terminal end sequences, circumvented its sticky nature, and successfully established a sandwich enzyme-linked immunosorbent assay (ELISA). Salusin-β was abundantly present in the plasma of healthy volunteers, ranging from 1.9 to 6.6 nmol/L. Reverse phase-high performance liquid chromatography analysis showed that a single immunoreactive salusin-β peak coincided with synthetic authentic salusin-β. Plasma salusin-β concentrations were unaffected by postural changes and by potent vasopressin release stimuli, such as hypertonic saline infusion or smoking. However, salusin-β concentrations showed significant circadian variation; concentrations were high during the daytime and reached the lowest concentrations in the early morning. Plasma salusin-β levels in subjects with diabetes mellitus, coronary artery disease, and cerebrovascular disease showed distinctly higher levels than healthy controls. Patients with panhypopituitarism combined with complete central diabetes insipidus also showed significantly higher plasma salusin-β levels. Therefore, the ELISA system developed in this study will be useful for evaluating circulating total salusin-β levels and for confirming the presence of authentic salusin-β in human plasma. The obtained results suggest a limited contribution of the neuroendocrine system to peripheral total salusin-β concentrations and a role for plasma total salusin-β concentrations as an indicator of systemic vascular diseases.

Indexed as

AdultAgedAged, 80 and overAnimalsAntibodiesAtherosclerosisCerebrovascular DisordersChickensChromatography, High Pressure LiquidCircadian RhythmCoronary Artery DiseaseDiabetes MellitusEnzyme-Linked Immunosorbent AssayFemaleHemodynamicsHumansAntibodiesIntercellular Signaling Peptides and ProteinsTOR2A protein, human

Identifiers

PMID24098553
PMCPMC3789687
OpenAlexW2027212700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.